Athero Review - Issue 2/2026
Guidelines
91
Semaglutide in the 2026 European Society of Cardiology guidelines
Michal Vrablík, Martin Šatný
clinical studies
95
The level of control of cardiovascular risk factors in patients with type 2 diabetes and hypertension in the routine clinical practice of primary care physicians: results of the BEAT study
Michal Vrablík, Martin Haluzík, Norbert Král, Barbora Turková, Michaela Vařejková, Tomáš Doležal
Reviews
100
Anti-atherosclerotic potential of SGLT2 inhibitors: what do the recent data show?
Branislav Vohnout, Jana Lisičanová
104
The role of DLCN in the diagnosis of familial hypercholesterolemia: data from the MedPed Center in Bratislava
Katarína Rašlová, Miloslava Hučková, Soňa Wimmerová, Ján Chandoga, Miriama Juhosová
109
Bempedoic acid in older adults: new data
Martin Šatný
113
Lipoprotein(a) and ischemic stroke
Darren Andrew Noronha, Martin Šatný, Michal Vrablík
119
Nanoplastics – is this really a new risk factor for cardiovascular disease?
Jaroslav A. Hubáček
From International Literature
Annoucements
126
129
Šobra Day 2026: From the roots of lipidology to its future
Kristýna Čillíková
Athero Review
2026 Issue 2
Most read in this issue
- Kardiovaskulární prevence v každodenní praxi
- Consensus on the treatment of hyperuricemia in individuals at high cardiovascular risk – update 2025: brief summary
- The level of control of cardiovascular risk factors in patients with type 2 diabetes and hypertension in the routine clinical practice of primary care physicians: results of the BEAT study
- Semaglutide in the 2026 European Society of Cardiology guidelines